Researchers from the University of Tasmania have developed a rapid diagnostic test that enables the identification, in field-collected samples, of very low levels of DNA from the two transmissible facial cancers that affect Tasmanian devils. The tool, based on CRISPR technology, could facilitate early detection of the diseases and improve surveillance and conservation management for this threatened species. developed
The two forms of transmissible facial tumor disease continue to contribute to the decline of Tasmanian devil populations. Until now, field detection depended largely on the presence of visible and sufficiently developed tumors. Laboratory molecular tests, in turn, are not easily applicable in remote locations, which makes monitoring the spread of the diseases difficult.
The new test, named SHERLOCK, was designed for field use and can detect very small amounts of tumor DNA from swab samples, without the need for invasive procedures. The researchers validated the method with field-collected samples, demonstrating its ability to identify both diseases.
The possibility of detecting the presence of tumors before they become visible could enable more effective surveillance and provide more timely information to guide conservation measures. The study, published in the journal The Royal Society, presents SHERLOCK as a diagnostic tool that can be used in locations distant from laboratories.